How do we treat patients with hereditary angioedema.
Hereditary angioedema (HAE) is due to the inherited deficiency of C1-Inhibitor (C1-Inh). When specific treatment was not available, the mortality rate for this disease was as high as 50% and the disability up to 100-150 days per year (Agostoni and Cicardi, Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients). Such a worrying scenario dramatically improves upon appropriate treatment. Nevertheless, the disease still frequently goes undiagnosed or misdiagnosed as an allergic condition. Both circumstances prevent patients from receiving drugs that could save and/or improve the quality of their life. The interest of our group for patients with HAE goes back to the early seventies. Since that time, 441 such patients have been examined and treated at our department; 403 are still actively followed. Here we present our experience on the treatment of HAE.
Cicardi
Marco
M
Department of Internal Medicine University of Milan, IRCCS Maggiore Hospital, Milan, Italy. Marco.Cicardi@unimi.it
Zingale
Lorenza
L
D000208:Acute Disease; D000328:Adult; D000728:Androgens / Q000627:therapeutic use; D000799:Angioedema / Q000235:genetics* / Q000517:prevention & control / Q000628:therapy*; D002648:Child; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome
D000728:Androgens; D003174:Complement C1 Inactivator Proteins